Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Patient’s characteristics

From: Systemic infection and microglia activation: a prospective postmortem study in sepsis patients

 Control N = 15Septic shock N = 16p-value
Female n (%)7 (46.7)5 (31.3)0.473
Age in years. Median (IQR)70.1 (65.2–87.4)68.6 (58.9–71.7)0.119
Living independently. N (%)13 (86.7)16 (100.0)0.226
N of chronic illnesses. Median (IQR)3 (1–4)2 (0–3)0.060
Medical history
 Diabetes. N (%)4 (26.7)4 (25.0)1.00
 Hypertension. N (%)11 (73.3)10 (62.5)0.704
 Heartfailure (NYHA ≥II). N (%)6 (40.0)1 (6.3)0.037
 Cardiac other. N (%)11 (73.3)8 (50.0)0.273
 Peripheral vasculopathy. N (%)2 (13.3)00.226
 Dyslipidemia. N (%)6 (40.0)2 (12.5)0.113
 CVA. N (%)3 (20.0)1 (6.3)0.333
 Chronic kidney disease (≥G3). N (%)5 (33.3)3 (18.8)0.433
 Livercirrhosis. N (%)01 (6.3)0.325
 COPD (GOLD≥2). N (%)02 (12.5)0.333
 Inflammatory disease. N (%)3 (20.0)1 (6.3)0.704
 Malignancy. N (%)4 (26.7)6 (37.5) 
 Immune compromised. N (%)00 
 Alcohol or drug abuse. N (%)1 (6.7)1 (6.3)1.00
 N regular medication. Median (IQR)7.5 (5.3–12.5)6 (2.0–12.0)0.223
Anticholinergic scores. Median (IQR)
 ACB score.2.5 (1.0–3.0)1.0 (0.0–2.8)0.146
 ARS score.0 (0–0)0 (0–0.75)0.423
  1. ACB anticholinergic cognitive burden list, ARS anticholinergic risk scale, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, NYHA New York heart association